Walleye Capital’s Amicus Therapeutics FOLD Stock Holding History

Walleye Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$223K	Sell	15,399 -10,631	-41%	-$152K	﹤0.01%	3275
2025 Q4	$371K	Sell	26,030 -480,831	-95%	-$4.72M	﹤0.01%	3145
2025 Q3	$3.99M	Buy	506,861 +470,443	+1,292%	+$3.35M	0.02%	1074
2025 Q2	$209K	Buy	+36,418	New	+$235K	﹤0.01%	3338
2025 Q1	–	Sell	-44,516	Closed	-$419K	–	4523
2024 Q4	$419K	Sell	44,516 -359,725	-89%	-$3.74M	﹤0.01%	3136
2024 Q3	$4.32M	Buy	404,241 +392,630	+3,382%	+$4.28M	0.01%	1281
2024 Q2	$115K	Sell	11,611 -10,733	-48%	-$110K	﹤0.01%	4648
2024 Q1	$263K	Buy	+22,344	New	+$286K	﹤0.01%	3769
2023 Q4	–	Sell	-172,169	Closed	-$2.09M	–	5133
2023 Q3	$2.09M	Buy	+172,169	New	+$2.22M	0.01%	1703
2022 Q1	–	Sell	-14,051	Closed	-$162K	–	2380
2021 Q4	$162K	Buy	+14,051	New	+$157K	0.01%	1541
2021 Q2	–	Sell	-33,600	Closed	-$332	–	1397
2021 Q1	$332	Buy	+33,600	New	+$520K	0.02%	718
2019 Q2	–	Sell	-414	Closed	-$5.25K	–	1839
2019 Q1	$6K	Buy	+414	New	+$5.06K	﹤0.01%	1433

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Walleye Capital's FOLD Position: Q1 2026 in Review

Walleye Capital reduced its Amicus Therapeutics (FOLD) stake by 41% in Q1 2026, selling an estimated $152K and leaving 15,399 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #3275.

Walleye Capital first reported a position in FOLD in Q1 2019 and has held it in 12 quarters since. The position peaked at $4.32M in Q3 2024. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Walleye Capital held 15,399 shares of Amicus Therapeutics worth $223K as of Q1 2026.
Walleye Capital sold 10,631 Amicus Therapeutics shares in Q1 2026, an estimated $152K.
Amicus Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3275 holding.
Walleye Capital first reported a position in Amicus Therapeutics in Q1 2019 and has held it in 12 quarters since.
Walleye Capital's Amicus Therapeutics position peaked at $4.32M in Q3 2024.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.